A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET). This study aims to investigate the safety profiles of sunitinib through data mining of the US...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Xusheng Zhang, Xiuli Ren, Tianyu Zhu, Wanjin Zheng, Chengwu Shen, Cuicui Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	sunitinib FDA adverse event reporting system disproportionality analyses pharmacovigilance adverse event
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1407709/full